Physician profile
Celeste Tunnell
NPI 1710925466
$3,191.98
in general payments reported to CMS, 2019-2025
26 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,194 · 2022: $330 · 2023: $1,108 · 2024: $166 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.82 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $800.00 | 2021 | |
| Abbvie INC. | $338.91 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $305.25 | 2022-2025 | |
| Astellas Pharma US INC | $276.14 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $249.58 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Exeltis, USA INC. | $182.40 | 2022-2023 | Slynd |
| Pfizer INC. | $159.70 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $111.52 | 2023-2025 | Myfembree |
| Organon LLC | $108.25 | 2021-2024 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $101.52 | 2021-2025 | |
| Myriad Women'S Health, INC. | $92.05 | 2023 | Myrisk |
| Myovant Sciences INC. | $67.09 | 2021-2022 | |
| Therapeuticsmd, INC. | $56.00 | 2021-2022 | |
| Sage Therapeutics, LLC | $51.95 | 2025 | Zurzuvae |
| Exact Sciences Corporation | $49.18 | 2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $39.97 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.98 | 2022 | |
| Avion Pharmaceuticals | $31.02 | 2021-2023 | Balcoltra |
| Mylan Pharmaceuticals INC. | $30.49 | 2021 | |
| Medicem INC. | $16.92 | 2022 | |
| Merck Sharp & Dohme LLC | $16.03 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.13 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $14.69 | 2024 | Injectafer |
| Becton, Dickinson and Company | $14.66 | 2024 | Bd Onclarity |
| Agile Therapeutics, INC. | $14.57 | 2022 | |
| Coopersurgical, INC. | $13.98 | 2025 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Tunnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.